Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

931
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
931
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Cost-effectiveness analysis of point-of-care tests for causes of non-malarial febrile illnesses in low-resource settings: a case study from Lao PDR.

BMJ public health·2026
Same author

Sub-RDT Plasmodium vivax infections and G6PD deficiency in Kayin State, Myanmar.

Malaria journal·2026
Same author

Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co-Infected With HIV.

Tropical medicine & international health : TM & IH·2026
Same author

Systematic review of economic evaluations in thalassaemia screening programmes globally: developing guidance for low- and middle-income (LMIC) settings.

BMJ open·2026
Same author

Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum.

Malaria journal·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: May 2, 2026

Injection of An. stephensi Embryos to Generate Malaria-resistant Mosquitoes
06:54

Injection of An. stephensi Embryos to Generate Malaria-resistant Mosquitoes

Published on: July 4, 2007

13.5K

マラリア

Elizabeth A Ashley1, Aung Pyae Phyo2, Charles J Woodrow3

  • 1Myanmar-Oxford Clinical Research Unit, Yangon, Myanmar; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Lancet (London, England)
|April 11, 2018
PubMed
まとめ
この要約は機械生成です。

ベッドネットと組み合わせた治療法による マラリア対策の進展にもかかわらず 重要な課題が残っています 薬剤耐性と資源の必要性が 世界的にマラリア撲滅の取り組みを阻害しています

さらに関連する動画

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes
15:03

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes

Published on: July 4, 2007

11.4K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.8K

関連する実験動画

Last Updated: May 2, 2026

Injection of An. stephensi Embryos to Generate Malaria-resistant Mosquitoes
06:54

Injection of An. stephensi Embryos to Generate Malaria-resistant Mosquitoes

Published on: July 4, 2007

13.5K
Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes
15:03

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes

Published on: July 4, 2007

11.4K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.8K

科学分野:

  • 世界保健
  • 感染症
  • 寄生虫学

背景:

  • マラリアは20世紀後半に 根絶の試みが失敗した後に再発しました
  • 昆虫駆除剤で処理されたベッドネットや アルテミシニンベースの組み合わせた治療法などの現在の制御手段は 全体の負担を軽減しましたが 負担は依然として大きいのです
  • 2016年にマラリアは44万5千人を超え 世界中で2億人以上が感染しました

研究 の 目的:

  • マラリア対策と撲滅の現状を見直す.
  • マラリア対策の継続的な課題と将来の方向性を特定する.

主な方法:

  • 最近の世界的なマラリア統計と傾向のレビュー.
  • 現在のマラリア対策戦略とその有効性の分析
  • 薬剤や殺虫剤に対する耐性やワクチン開発などの課題について議論

主要な成果:

  • 世界的なマラリアの負担は著しく減ったものの,依然として高く,2016年には2億人以上が感染し,44万5千人が死亡しました.
  • 個々の患者管理の落とし穴には,診断の遅延と重度のマラリアの過剰な液体蘇生が含まれます.
  • 寄生虫の再発は,高寄生虫密度,低免疫力,または薬剤耐性がない場合でも,最適でない薬剤レベルなどの要因によって起こる可能性があります.

結論:

  • マラリアの撲滅は 重要な政策目標ですが アルテミシニンや 副薬や 殺虫剤に対する耐性が 大きな脅威となっています
  • 現在のマラリアワクチンは 長期に渡って 人口レベルでの効果を示していない.
  • マラリアの負担をさらに軽減するには,より多くの資源,地域協力,社会的コミットメントが必要です.